ProCE Banner Activity

CE / CME

Today’s Concepts in EGFR TKIs for NSCLC

Multimedia
Watch this CME-certified on-demand Webcast of a CCO symposium at AMCP 2019 to gain expert pharmacist and oncologist perspectives on the evolving role of EGFR TKIs in EGFR-mutated NSCLC, including EGFR TKI pharmacology, selecting optimal treatment across the disease course based on the latest clinical data, cost and access considerations, and a panel discussion.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Nurses: 1.50 Nursing contact hours

Released: May 09, 2019

Expiration: May 08, 2020

No longer available for credit.

Share

Faculty

Val R. Adams

Val R. Adams, PharmD, FCCP, BCOP

Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky
Lexington, Kentucky

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Philip Schwieterman

Philip Schwieterman, PharmD, MHA

Director of Oncology and Pediatric Pharmacy
Markey Cancer Center
UK Health Care
Lexington, Kentucky

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Target Audience

This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Examine current recommendations for molecular testing and the roles for liquid biopsies in guiding therapy, especially as it relates to activating and nonactivating EGFR mutations and EGFR T790M mutations
  • Compare current and emerging frontline treatment strategies for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors
  • Compare evidence of efficacy in delaying or reducing brain metastases for the different EGFR TKIs
  • Evaluate current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated NSCLC
  • Discuss the roles of oncology and managed care pharmacists in optimizing the use of targeted therapy in advanced EGFR-mutated NSCLC, managing therapy-related toxicities, improving adherence, educating patients, and aiding in the implementation of clinical pathways to deliver quality care

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Val R. Adams, PharmD, FCCP, BCOP

Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky
Lexington, Kentucky

Val R. Adams, PharmD, FCCP, BCOP, has no real or apparent conflicts of interest to report.

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech/Roche, Heron, and Takeda and funds for research support from Celgene, Merck, Novartis, and OncoMed.

Philip Schwieterman, PharmD, MHA

Director of Oncology and Pediatric Pharmacy
Markey Cancer Center
UK Health Care
Lexington, Kentucky

Philip Schwieterman, PharmD, MHA, has no real or apparent conflicts of interest to report.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Credit Designation

CCO designates this continuing education activity for 1.5 contact hour (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008176-0000-19-015-H01-P)

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 09, 2019, through May 08, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to educate pharmacists and managed care professionals about advances in the clinical management of patients with EGFR mutation–positive non-small-cell lung cancer.